Impact News +++ UniQure Shares Drop After FDA Shifts Stance On Huntington′s Gene Therapy Data (Benzinga) +++ UNIQURE Aktie +4,91%

TERNS PHARMACEUTICALS Aktie

>TERNS PHARMA Aktienkurs

12.6 EUR +75.0% (Tradegate)

Ask: 12.4 EUR / 810 Stück

Bid: 12.3 EUR / 820 Stück

Tagesumsatz: 12696 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TERNS PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>TERNS PHARMA Performance

1 Woche: +9,2%

1 Monat: +9,2%

3 Monate: +39,2%

6 Monate: +153,6%

1 Jahr: +11,8%

laufendes Jahr: +30,3%

>TERNS PHARMACEUTICALS Aktie

Name:

TERNS PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8808811074 / A2QNWR

Symbol/ Ticker:

430 (Frankfurt) / TERN (NASDAQ)

Kürzel:

FRA:430, ETR:430, 430:GR, NASDAQ:TERN

Index:

Webseite:

https://www.ternspharma.c..

Profil:

Terns Pharmaceuticals Inc. is a biopharmaceutical ..
>Volltext..

Marktkapitalisierung:

626.5 Mio. EUR

Unternehmenswert:

359 Mio. EUR

Umsatz:

EBITDA:

-91.01 Mio. EUR

Nettogewinn:

-79.52 Mio. EUR

Gewinn je Aktie:

-0.91 EUR

Schulden:

0.98 Mio. EUR

Liquide Mittel:

126.51 Mio. EUR

Operativer Cashflow:

-64.78 Mio. EUR

Bargeldquote:

24.43

Umsatzwachstum:

Gewinnwachstum:

13.01%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TERNS PHARMACEUTICALS, TERNS PHARMA, TERNS PHARMACEUTICAL

Letzte Datenerhebung:

03.11.25

>TERNS PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 87.51 Mio. St.

Frei handelbar: 79.57%

Leerverk. Aktien: 11.84%

Rückkaufquote: -22.74%

Mitarbeiter: 59

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 152.59%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.82

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -33.28%

Eigenkaprendite: -35.02%

>TERNS PHARMA Peer Group

Es sind 597 Aktien bekannt.

>TERNS PHARMA Chart & Kurs - NASDAQ

>TERNS PHARMA News

03.11.25 - 20:18

Terns Pharmaceuticals′ Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades (Benzinga)

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform. Latest Ratings for NVS DateFirmActionFromTo Dec 2021Exane BNP ParibasDowngradesOutperformNeutral Dec 2021Bryan GarnierDowngradesBuyNeutral Sep 2021Deutsche BankDowngradesHoldSell View More Analyst Ratings for NVS View the Latest Analyst Ratings read more...

03.11.25 - 15:48	Terns Pharmaceuticals: Aktie schießt nach vielversprechenden Daten zu Leukämie-Therapie in die Höhe/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

21.10.25 - 23:06	Terns Pharmaceuticals: Aktie stürzt nach enttäuschenden Studienergebnissen zu Adipositas-Medikament ab (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

21.10.25 - 22:09	Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity (GlobeNewswire EN)
	Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events...

03.10.25 - 02:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Terns Pharmaceuticals im Wert von 7407 USD (Insiderkauf)
	Kuriakose, Emil - Vorstand - Tag der Transaktion: 2025-10-01...

02.10.25 - 22:09

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire EN)

FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns....

21.08.25 - 22:09	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 (GlobeNewswire EN)
	Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET...

05.08.25 - 23:30	Terns Pharmaceuticals GAAP EPS of -$0.26 beats by $0.03 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.07.25 - 02:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Terns Pharmaceuticals im Wert von 3640 USD (Insiderkauf)
	Kuriakose, Emil - Vorstand - Tag der Transaktion: 2025-07-01...

01.07.25 - 04:01	Insiderhandel: Chief Financial Officer kauft Aktien von Terns Pharmaceuticals im Wert von 39284 USD (Insiderkauf)
	Gengos, Andrew - Vorstand - Tag der Transaktion: 2025-06-27...

26.06.25 - 01:01	Insiderhandel: Chief Executive Officer kauft Aktien von Terns Pharmaceuticals im Wert von 90230 USD (Insiderkauf)
	Burroughs, Amy L. - Vorstand - Tag der Transaktion: 2025-06-25...

23.06.25 - 22:09	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire EN)
	Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024...

17.06.25 - 04:01	Insiderhandel: Chief Financial Officer kauft Aktien von Terns Pharmaceuticals im Wert von 19733 USD (Insiderkauf)
	Gengos, Andrew - Vorstand - Tag der Transaktion: 2025-06-16...

17.06.25 - 04:01	Insiderhandel: Chief Financial Officer kauft Aktien von Terns Pharmaceuticals im Wert von 37350 USD (Insiderkauf)
	Gengos, Andrew - Vorstand - Tag der Transaktion: 2025-06-13...

29.05.25 - 22:06

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire EN)

FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June....

14.05.25 - 15:33	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 (GlobeNewswire EN)
	Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations...

09.05.25 - 19:48	Terns Pharmaceuticals GAAP EPS of -$0.26 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.05.25 - 22:06

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire EN)

FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns....

30.04.25 - 22:09

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference (GlobeNewswire EN)

FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET....

07.04.25 - 16:45	Down -39.83% in 4 Weeks, Here′s Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround (Zacks)
	Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die deutschen politischen Schriftsteller, nicht an Geist fehlt es ihnen, aber an Mut. - Ludwig Börne

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram